OBJECTIVES: To study the comparative mortality associated with carbapenems and alternative antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive Enterobacteriaceae bacteraemia. METHODS: We searched systematically PubMed and Scopus databases for studies providing data for mortality among patients treated with carbapenems, β-lactam/β-lactamase inhibitor combinations (BL/BLIs) or non-BL/BLIs (mainly cephalosporins and fluoroquinolones), preferably as monotherapy. Studies focusing on patients of all ages with community- and healthcare-associated bacteraemia were eligible. Data were pooled using the technique of meta-analysis. RESULTS: Twenty-one articles, studying 1584 patients, were included. Escherichia coli and Klebsiella pneumoniae were the most commonly studied bacteria. Delay in appropriate treatment up to 6 days was reported. Carbapenems were used mainly as definitive therapy. Carbapenems were associated with lower mortality than non- BL/BLIs for definitive [risk ratio (RR) 0.65, 95% CI 0.47-0.91] and empirical (RR 0.50, 95% CI 0.33-0.77) treatment. No statistically significant differences in mortality were found between carbapenems and BL/BLIs administered as definitive (RR 0.52, 95% 0.23-1.13) or empirical (RR 0.91, 95% CI 0.66-1.25) treatment. BL/BLIs were not associated with lower mortality than non-BL/BLIs administered either definitively (RR 1.59, 95% 0.83-3.06) or empirically (RR 0.82, 95% 0.48-1.41). Data regarding subgroups according to the setting, comorbidity and bacterial species could not be extracted. CONCLUSIONS: Based on data from non-randomized studies, carbapenems may be considered the treatment of choice for empirical treatment of patients with ESBL-producing Enterobacteriaceae bacteraemia. The role of BL/BLIs should be further evaluated for definitive treatment. Further research should focus on faster identification of ESBL-positive pathogens and potential differences in the treatment of each bacterial species.
OBJECTIVES: To study the comparative mortality associated with carbapenems and alternative antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive Enterobacteriaceae bacteraemia. METHODS: We searched systematically PubMed and Scopus databases for studies providing data for mortality among patients treated with carbapenems, β-lactam/β-lactamase inhibitor combinations (BL/BLIs) or non-BL/BLIs (mainly cephalosporins and fluoroquinolones), preferably as monotherapy. Studies focusing on patients of all ages with community- and healthcare-associated bacteraemia were eligible. Data were pooled using the technique of meta-analysis. RESULTS: Twenty-one articles, studying 1584 patients, were included. Escherichia coli and Klebsiella pneumoniae were the most commonly studied bacteria. Delay in appropriate treatment up to 6 days was reported. Carbapenems were used mainly as definitive therapy. Carbapenems were associated with lower mortality than non- BL/BLIs for definitive [risk ratio (RR) 0.65, 95% CI 0.47-0.91] and empirical (RR 0.50, 95% CI 0.33-0.77) treatment. No statistically significant differences in mortality were found between carbapenems and BL/BLIs administered as definitive (RR 0.52, 95% 0.23-1.13) or empirical (RR 0.91, 95% CI 0.66-1.25) treatment. BL/BLIs were not associated with lower mortality than non-BL/BLIs administered either definitively (RR 1.59, 95% 0.83-3.06) or empirically (RR 0.82, 95% 0.48-1.41). Data regarding subgroups according to the setting, comorbidity and bacterial species could not be extracted. CONCLUSIONS: Based on data from non-randomized studies, carbapenems may be considered the treatment of choice for empirical treatment of patients with ESBL-producing Enterobacteriaceae bacteraemia. The role of BL/BLIs should be further evaluated for definitive treatment. Further research should focus on faster identification of ESBL-positive pathogens and potential differences in the treatment of each bacterial species.
Authors: Patrick McGann; Erik Snesrud; Ana C Ong; Lakshmi Appalla; Michael Koren; Yoon I Kwak; Paige E Waterman; Emil P Lesho Journal: Antimicrob Agents Chemother Date: 2015-04-13 Impact factor: 5.191
Authors: Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: T Delory; A De Pontfarcy; A Emirian; F About; B Berdougo; C Brun-Buisson; P Lesprit Journal: Eur J Clin Microbiol Infect Dis Date: 2013-07-10 Impact factor: 3.267
Authors: Belén Gutiérrez-Gutiérrez; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Benito Almirante; Luis Martínez-Martínez; Antonio Oliver; Esther Calbo; Carmen Peña; Murat Akova; Johann Pitout; Julia Origüen; Vicente Pintado; Elisa García-Vázquez; Oriol Gasch; Axel Hamprecht; Nuria Prim; Mario Tumbarello; German Bou; Pierluigi Viale; Evelina Tacconelli; Manel Almela; Federico Pérez; Helen Giamarellou; José Miguel Cisneros; Mitchell J Schwaber; Mario Venditti; Warren Lowman; Joaquín Bermejo; Po-Ren Hsueh; Marta Mora-Rillo; Irene Gracia-Ahulfinger; Alvaro Pascual; Jesús Rodríguez-Baño Journal: J Antimicrob Chemother Date: 2016-02-22 Impact factor: 5.790
Authors: J-H Ko; N R Lee; E-J Joo; S-Y Moon; J-K Choi; D A Park; K R Peck Journal: Eur J Clin Microbiol Infect Dis Date: 2017-11-25 Impact factor: 3.267